SATT Aquitaine has decided to invest \u20ac317,890 (including \u20ac40,000 in intellectual property) in the development of the NOVEL project, a breakthrough innovation aimed at developing a modifier treatment for Parkinson’s disease and multiple system atrophy. There is currently no treatment available to slow the progression of these two neurodegenerative diseases, which are among the most debilitating.<\/p>\n
The aim of the NOVEL project is to restore the ability of cells to break down misfolded proteins and their aggregates. The strategy is based on a nanovector designed to target lysosomes (key organelles in cellular degradation) and increase their ability to break down \u03b1-synuclein. This approach aims to slow down or even stabilize the progression of the disease. It would offer patients a better quality of life and prolonged autonomy, as well as a later increase in doses of dopaminergic treatments, thereby reducing their side effects.<\/p>\n
NOVEL is supported by a multidisciplinary research team combining complementary expertise in neuroscience and chemistry. The project was initiated by Benjamin Dehay, Inserm Research Director at the Institute for Neurodegenerative Diseases (IMN \u2013 University of Bordeaux, CNRS), S\u00e9bastien Lecommandoux, Professor at Bordeaux INP and Director of the Organic Polymer Chemistry Laboratory (LCPO \u2013 University of Bordeaux, CNRS, Bordeaux INP) and Philippe Barth\u00e9l\u00e9my, Director of the Nucleic Acids: Natural and Artificial Regulations Laboratory (ARNA \u2013 Inserm, CNRS, University of Bordeaux).<\/p>\n